Chimigen Biotec

Chimigen Biotec is a clinical-stage biotechnology company specializing in the development of innovative therapeutic and prophylactic vaccines for infectious diseases and oncology. The company utilizes its proprietary Chimigen platform technology to create chimeric fusion proteins that efficiently deliver antigens to antigen-presenting cells, thereby enhancing the immune response. Its lead candidate is a therapeutic vaccine for chronic Hepatitis B, which has undergone clinical evaluation in China. Beyond Hepatitis B, the company is applying its platform to develop treatments for Hepatitis C, influenza, and various cancers. Chimigen operates facilities in both Beijing, China, and the United States, focusing on addressing significant unmet medical needs in global health.